Verition Fund Management
PRTK

Verition Fund Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Verition Fund Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,766
Closed -$37K – 2695
2022
Q4 		$37K Buy
+19,766
New +$49.3K ﹤0.01% 1901
2020
Q2 		– Sell
-81,010
Closed -$255K – 1190
2020
Q1 		$255K Buy
+81,010
New +$299K 0.01% 460
2017
Q4 		– Sell
-10,473
Closed -$263K – 1317
2017
Q3 		$263K Buy
+10,473
New +$244K 0.02% 940

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Verition Fund Management's PRTK Position: Q1 2023 in Review

Verition Fund Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 19,766 shares — an estimated $37K sold.

Verition Fund Management first reported a position in PRTK in Q3 2017 and held it in 3 quarters. The position peaked at $263K in Q3 2017. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

  • Verition Fund Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Verition Fund Management sold 19,766 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $37K.
  • Verition Fund Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
  • Verition Fund Management's Paratek Pharmaceuticals, Inc. position peaked at $263K in Q3 2017.
  • 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.